StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.29−0.21 (-0.31%)

Close on Nov 18, 2026Market cap $16.66BP/E 20.4Yield –

Exelixis operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Exelixis's operating income for the twelve months ending Oct 2, 2026 was $1.00B, up 25.4% year over year. For fiscal 2025 it was $872.19M, up 44.3% from the year before. The highest annual figure on record is $872.19M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Jan 2, 2026$872.19M+44.3%
FY2024Jan 3, 2025$604.62M+253.8%
FY2023Dec 29, 2023$170.89M-15.2%
FY2022Dec 30, 2022$201.48M-29.7%
FY2021Dec 31, 2021$286.67M+160.5%
FY2020Jan 1, 2021$110.06M-70.2%
FY2019Jan 3, 2020$369.47M-15.8%
FY2018Dec 28, 2018$438.86M+164.5%
FY2017Dec 29, 2017$165.91M–
FY2016Dec 31, 2016-$28.12M–
FY2015Dec 31, 2015-$121.42M–
FY2014Dec 31, 2014-$224.46M–
FY2013Dec 31, 2013-$200.73M–
FY2012Dec 31, 2012-$122.44M-236.7%
FY2011Dec 31, 2011$89.54M–
FY2010Dec 31, 2010-$91.40M–
FY2009Dec 31, 2009-$121.91M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Oct 2, 2026$268.42M+13.5%
Q2 FY2026Jul 3, 2026$248.41M+16.3%
Q1 FY2026Apr 3, 2026$251.34M+34.5%
Q4 FY2025Jan 2, 2026$235.22M+44.1%
Q3 FY2025Oct 3, 2025$236.54M+73.8%
Q2 FY2025Jul 4, 2025$213.58M-22.6%
Q1 FY2025Apr 4, 2025$186.86M+534.2%
Q4 FY2024Jan 3, 2025$163.21M+99.5%
Q3 FY2024Sep 27, 2024$136.08M–
Q2 FY2024Jun 28, 2024$275.87M+254.4%
Q1 FY2024Mar 29, 2024$29.46M+2.2%
Q4 FY2023Dec 29, 2023$81.79M–
Q3 FY2023Sep 29, 2023-$17.58M-121.3%
Q2 FY2023Jun 30, 2023$77.85M-7.0%
Q1 FY2023Mar 31, 2023$28.83M-65.4%
Q4 FY2022Dec 30, 2022-$48.08M-141.2%
Q3 FY2022Sep 30, 2022$82.61M+60.0%
Q2 FY2022Jul 1, 2022$83.71M-32.0%
Q1 FY2022Apr 1, 2022$83.24M–
Q4 FY2021Dec 31, 2021$116.64M+380.1%
Q3 FY2021Oct 1, 2021$51.62M–
Q2 FY2021Jul 2, 2021$123.01M+62.9%
Q1 FY2021Apr 2, 2021-$4.61M-108.7%
Q4 FY2020Jan 1, 2021$24.30M-68.6%
Q3 FY2020Oct 2, 2020-$42.58M-136.8%
Q2 FY2020Jul 3, 2020$75.53M-17.9%
Q1 FY2020Apr 3, 2020$52.81M-37.5%
Q4 FY2019Jan 3, 2020$77.32M-30.7%
Q3 FY2019Sep 27, 2019$115.61M-7.6%
Q2 FY2019Jun 28, 2019$91.99M+7.3%
Q1 FY2019Mar 29, 2019$84.56M-27.3%
Q4 FY2018Dec 28, 2018$111.60M+198.2%
Q3 FY2018Sep 28, 2018$125.18M+54.2%
Q2 FY2018Jun 29, 2018$85.77M+216.3%
Q1 FY2018Mar 30, 2018$116.31M+476.2%
Q4 FY2017Dec 29, 2017$37.43M-3.7%
Q3 FY2017Sep 30, 2017$81.18M–
Q2 FY2017Jun 30, 2017$27.11M–
Q1 FY2017Mar 31, 2017$20.19M–
Q4 FY2016Dec 31, 2016$38.88M–

More Exelixis figures

See a number that looks wrong?